Back to search

Netherlands· NL-a4c352fa3ff2

Berinert 3000 IE, poeder en oplosmiddel voor oplossing voor injectie

A c1-inhibitor, plasma derived product containing c1-esteraseremmer, registered in Netherlands by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC B06AC01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBerinert 3000 IE, poeder en oplosmidd…ATCB06AC01REGISTER NO.NL-a4c352fa3ff2PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

C1-inhibitor, plasma derived is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC01 (c1-inhibitor, plasma derived), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

C1-inhibitor, plasma derived · ATC B06AC01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
C1-ESTERASEREMMER
Manufacturer
CSL Behring GmbH
Country
Netherlands (NL)
ATC code
B06AC01
ATC class
C1-inhibitor, plasma derived
Defined daily dose
1.4 TSD, E
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    127905

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

47 interactions on record for c1-inhibitor, plasma derived.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

C1-inhibitor, plasma derived · interactions on record

47 records

  • 5 severe
  • 42 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f40b5eb4-73b8-4124-b592-b8f7d1b142e2
GET /v1/drugs/f40b5eb4-73b8-4124-b592-b8f7d1b142e2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h127905_smpc.pdf",
  "strength": null,
  "atc_label": "C1-inhibitor, plasma derived",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg127905",
  "excipients": [
    "GLYCINE (E 640)",
    "NATRIUMCHLORIDE",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "C1-ESTERASEREMMER"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h127905.pdf",
  "authorised_at": "2021/09/06",
  "procedure_number": "DE/H/0481/004",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "127905",
  "additional_monitoring": "N"
}

See everything about c1-inhibitor, plasma derived.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.